메뉴 건너뛰기




Volumn 12, Issue 3, 2012, Pages 319-333

When is switching warranted among biologic therapies in rheumatoid arthritis?

Author keywords

biologic therapy; effectiveness; rheumatoid arthritis; safety; switching; TNF antagonist

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 84864209715     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.27     Document Type: Review
Times cited : (31)

References (82)
  • 1
    • 77950307115 scopus 로고    scopus 로고
    • T2T Expert committee treating rheumatoid arthritis to target: Recommendations of an international task force
    • Smolen JS, Aletaha D, Bijlsma JW et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann. Rheum. is. 69(4), 631-637 (2010
    • (2010) Ann. Rheum. Is. , vol.69 , Issue.4 , pp. 631-637
    • Smolen, J.S.1    Aletaha, D.2    Bijlsma, J.W.3
  • 2
    • 2342658406 scopus 로고    scopus 로고
    • Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody)in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial
    • Keystone EC, KaVanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody)in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50(5), 1400-1411 (2004)
    • (2004) Arthritis Rheum. , vol.50 , Issue.5 , pp. 1400-1411
    • Keystone, E.C.1    KaVanaugh, A.F.2    Sharp, J.T.3
  • 3
    • 10744223002 scopus 로고    scopus 로고
    • TEMPO (Trial of etanercept and methotrexate with radiographic patient outcomes)study investigators therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
    • Klareskog L, Van der Heijde D, de Jager JP et al.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes)Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004
    • (2004) Lancet , vol.363 , Issue.9410 , pp. 675-681
    • Klareskog, L.1    Van Der Heijde, D.2    De Jager, J.P.3
  • 4
    • 8444239359 scopus 로고    scopus 로고
    • Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
    • St Clair EW, Van der Heijde DM, Smolen JS et al.; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004
    • (2004) Arthritis Rheum. , vol.50 , Issue.11 , pp. 3432-3443
    • St Clair, E.W.1    Van Der Heijde, D.M.2    Smolen, J.S.3
  • 6
    • 64549161956 scopus 로고    scopus 로고
    • Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: A critical review
    • Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: A critical review. Arthritis Res. Ther. 11(Suppl. 1), S1 (2009
    • (2009) Arthritis Res. Ther. , vol.11 , Issue.SUPPL. 1
    • Rubbert-Roth, A.1    Finckh, A.2
  • 7
    • 34147219117 scopus 로고    scopus 로고
    • Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis data from the Spanish registry BIOBADASER
    • Biobadaser Group
    • Carmona L, Gómez-Reino JJ; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res. Ther. 8(3), R72 (2006
    • (2006) Arthritis Res. Ther. , vol.8 , Issue.3
    • Carmona, L.1    Gómez-Reino, J.J.2
  • 8
    • 36749002002 scopus 로고    scopus 로고
    • Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis results from a six-year observational study in southern Sweden
    • Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res. Ther. 8(6), R174 (2006
    • (2006) Arthritis Res. Ther. , vol.8 , Issue.6
    • Kristensen, L.E.1    Saxne, T.2    Nilsson, J.A.3    Geborek, P.4
  • 9
    • 39449132386 scopus 로고    scopus 로고
    • The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study
    • Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study. Arthritis Rheum. 59(2), 234-240 (2008
    • (2008) Arthritis Rheum. , vol.59 , Issue.2 , pp. 234-240
    • Heiberg, M.S.1    Koldingsnes, W.2    Mikkelsen, K.3
  • 10
    • 50249107555 scopus 로고    scopus 로고
    • The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data
    • Kievit W, Adang EM, Fransen J et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann. Rheum. Dis. 67(9), 1229-1234 (2008
    • (2008) Ann. Rheum. Dis. , vol.67 , Issue.9 , pp. 1229-1234
    • Kievit, W.1    Adang, E.M.2    Fransen, J.3
  • 11
    • 70049109275 scopus 로고    scopus 로고
    • TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
    • Marchesoni A, Zaccara E, Gorla R et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann. NY Acad. Sci. 1173, 837-846 (2009
    • (2009) Ann. NY Acad. Sci. , vol.1173 , pp. 837-846
    • Marchesoni, A.1    Zaccara, E.2    Gorla, R.3
  • 12
    • 74849094402 scopus 로고    scopus 로고
    • All departments of rheumatology in denmark direct comparison of treatment responses, remission rates, and drug dherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
    • Hetland ML, Christensen IJ, Tarp U et al.; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug dherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 62(1), 22-32 (2010
    • (2010) Arthritis Rheum. , vol.62 , Issue.1 , pp. 22-32
    • Hetland, M.L.1    Christensen, I.J.2    Tarp, U.3
  • 13
    • 79952359578 scopus 로고    scopus 로고
    • Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: Results from the british society for rheumatology biologics register
    • British Society for Rheumatology Biologics Register
    • Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70(4), 583-589 (2011)
    • (2011) Ann. Rheum. Dis. , vol.70 , Issue.4 , pp. 583-589
    • Soliman, M.M.1    Ashcroft, D.M.2    Watson, K.D.3    Lunt, M.4    Symmons, D.P.5    Hyrich, K.L.6
  • 14
    • 33845593147 scopus 로고    scopus 로고
    • Use of tumor necrosis factor inhibitors in rheumatoid arthritis: A national survey of practicing united states rheumatologists
    • Kamal KM, MadhaVan SS, Hornsby JA, Miller LA, Kavookjian J, Scott V. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: A national survey of practicing United States rheumatologists. Point Bone Spine 73(6), 718-724 (2006
    • (2006) Point Bone Spine , vol.73 , Issue.6 , pp. 718-724
    • Kamal, K.M.1    MadhaVan, S.S.2    Hornsby, J.A.3    Miller, L.A.4    Kavookjian, J.5    Scott, V.6
  • 15
    • 45349090538 scopus 로고    scopus 로고
    • American college of rheumatology american college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    • Saag KG, Teng GG, Patkar NM et al.; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. rthritis Rheum. 59(6), 762-784 (2008
    • (2008) Rthritis Rheum , vol.59 , Issue.6 , pp. 762-784
    • Saag, K.G.1    Teng, G.G.2    Patkar, N.M.3
  • 16
    • 77953696525 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    • Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010
    • (2010) Ann. Rheum. Dis. , vol.69 , Issue.6 , pp. 964-975
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3
  • 17
    • 75749141648 scopus 로고    scopus 로고
    • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
    • Furst DE, Keystone EC, Fleischmann R et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis. 69(Suppl. 1), i2-i29 (2010
    • (2010) Ann. Rheum. Dis. , Issue.69 SUPPL. 1
    • Furst, D.E.1    Keystone, E.C.2    Fleischmann, R.3
  • 18
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    • Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005
    • (2005) N. Engl. J. Med. , vol.353 , Issue.11 , pp. 1114-1123
    • Genovese, M.C.1    Becker, J.C.2    Schiff, M.3
  • 19
    • 33746961890 scopus 로고    scopus 로고
    • Reflex trial group rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • Cohen SB, Emery P, Greenwald MW et al.; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793-2806 (2006
    • (2006) Arthritis Rheum. , vol.54 , Issue.9 , pp. 2793-2806
    • Cohen, S.B.1    Emery, P.2    Greenwald, M.W.3
  • 20
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
    • Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67(11), 1516-1523 (2008
    • (2008) Ann. Rheum. Dis. , vol.67 , Issue.11 , pp. 1516-1523
    • Emery, P.1    Keystone, E.2    Tony, H.P.3
  • 21
    • 77952746394 scopus 로고    scopus 로고
    • Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
    • Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 10(3), 308-315 (2010
    • (2010) Curr. Opin. Pharmacol. , vol.10 , Issue.3 , pp. 308-315
    • Taylor, P.C.1
  • 22
    • 77951974496 scopus 로고    scopus 로고
    • To switch or to change class-The biologic dilemma in rheumatoid arthritis
    • Villeneuve E, Haraoui B. To switch or to change class-the biologic dilemma in rheumatoid arthritis. Nat. Rev. Rheumatol. 6(5), 301-305 (2010
    • (2010) Nat. Rev. Rheumatol. , vol.6 , Issue.5 , pp. 301-305
    • Villeneuve, E.1    Haraoui, B.2
  • 23
    • 67650379733 scopus 로고    scopus 로고
    • GO-After study Investigators golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO- FTER study): A multicentre, randomised, double-blind, placebocontrolled, Phase III trial
    • Smolen JS, Kay J, Doyle MK et al.; GO-AFTER Study Investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO- FTER study): A multicentre, randomised, double-blind, placebocontrolled, Phase III trial. Lancet 374(9685), 210-221 (2009
    • (2009) Lancet , vol.374 , Issue.9685 , pp. 210-221
    • Smolen, J.S.1    Kay, J.2    Doyle, M.K.3
  • 24
    • 78549233711 scopus 로고    scopus 로고
    • The effectiveness of anti-TNFalpha therapies when used sequentially in rheumatoid arthritis patients: A systematic review and meta-analysis
    • Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNFalpha therapies when used sequentially in rheumatoid arthritis patients: A systematic review and meta-analysis. Rheumatology 49(12), 2313-2321 (2010
    • (2010) Rheumatology , vol.49 , Issue.12 , pp. 2313-2321
    • Lloyd, S.1    Bujkiewicz, S.2    Wailoo, A.J.3    Sutton, A.J.4    Scott, D.5
  • 25
    • 79955650444 scopus 로고    scopus 로고
    • Clinical releVance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: A systematic literature review and meta-analysis
    • Rémy A, Avouac J, Gossec L, Combe B. Clinical releVance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: A systematic literature review and meta-analysis. Clin. Exp. Rheumatol. 29(1), 96-103 (2011
    • (2011) Clin. Exp. Rheumatol. , vol.29 , Issue.1 , pp. 96-103
    • Rémy, A.1    Avouac, J.2    Gossec, L.3    Combe, B.4
  • 26
    • 79951555321 scopus 로고    scopus 로고
    • Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-A inhibitors
    • Rendas-Baum R, Wallenstein GV, Koncz T et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-a inhibitors. Arthritis Res. Ther. 13(1), R25 (2011
    • (2011) Arthritis Res. Ther. , vol.13 , Issue.1
    • Rendas-Baum, R.1    Wallenstein, G.V.2    Koncz, T.3
  • 27
    • 77950237515 scopus 로고    scopus 로고
    • Sequential use of biologic therapy in rheumatoid arthritis
    • Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 22(3), 321-329 (2010
    • (2010) Curr. Opin. Rheumatol. , vol.22 , Issue.3 , pp. 321-329
    • Buch, M.H.1
  • 28
    • 2942537697 scopus 로고    scopus 로고
    • Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    • Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004
    • (2004) N. Engl. J. Med. , vol.350 , Issue.25 , pp. 2572-2581
    • Edwards, J.C.1    Szczepanski, L.2    Szechinski, J.3
  • 29
    • 0242574700 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
    • Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907-1915 (2003
    • (2003) N. Engl. J. Med. , vol.349 , Issue.20 , pp. 1907-1915
    • Kremer, J.M.1    Westhovens, R.2    Leon, M.3
  • 30
    • 33749363027 scopus 로고    scopus 로고
    • Charisma study group double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    • Maini RN, Taylor PC, Szechinski J et al.; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817-2829 (2006)
    • (2006) Arthritis Rheum. , vol.54 , Issue.9 , pp. 2817-2829
    • Maini, R.N.1    Taylor, P.C.2    Szechinski, J.3
  • 31
    • 75749106664 scopus 로고    scopus 로고
    • Arthritis which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF)agents after previous failure of an anti-TNF agent
    • Finckh A, Ciurea A, Brulhart L et al.; Arthritis. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF)agents after previous failure of an anti-TNF agent? Ann. Rheum. Dis. 69(2), 387-393 (2010
    • (2010) Ann. Rheum. Dis. , vol.69 , Issue.2 , pp. 387-393
    • Finckh, A.1    Ciurea, A.2    Brulhart, L.3
  • 32
    • 77950291722 scopus 로고    scopus 로고
    • Is switching to rituximab more effective than switching to an alternative tumour necrosis factor blocking therapy (TNF-BT)in patients with rheumatoid arthritis (RA)who have failed a previous TNF-BT? Single-centre cohort experience
    • Buch M, Dass S, Vital EM et al. Is switching to rituximab more effective than switching to an alternative tumour necrosis factor blocking therapy (TNF-BT)in patients with rheumatoid arthritis (RA)who have failed a previous TNF-BT? Single-centre cohort experience. Ann. Rheum. Dis. 68(Suppl. 3), 574 (2009
    • (2009) Ann. Rheum. Dis. , vol.68 , Issue.SUPPL. 3 , pp. 574
    • Buch, M.1    Dass, S.2    Vital, E.M.3
  • 33
    • 77951975383 scopus 로고    scopus 로고
    • Rituximab versus anti-TNF in patients who previously failed one or more anti-TNFs in an observational cohort: The SARASTRA study
    • Chatzidionysiou K, Carl C, Van Vollenhoven RF. Rituximab versus anti-TNF in patients who previously failed one or more anti-TNFs in an observational cohort: The SARASTRA study. Ann. Rheum. Dis. 68(Suppl. 3), 445 (2009
    • (2009) Ann. Rheum. Dis. , vol.68 , Issue.SUPPL. 3 , pp. 445
    • Chatzidionysiou, K.1    Carl, C.2    Van Vollenhoven, R.F.3
  • 34
    • 70449709528 scopus 로고    scopus 로고
    • The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial
    • Schiff M, Pritchard C, Huffstutter JE et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial. Ann. Rheum. Dis. 68(11), 1708-1714 (2009
    • (2009) Ann. Rheum. Dis. , vol.68 , Issue.11 , pp. 1708-1714
    • Schiff, M.1    Pritchard, C.2    Huffstutter, J.E.3
  • 35
    • 45049086041 scopus 로고    scopus 로고
    • Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
    • Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin. Rheumatol. 27(7), 927-932 (2008
    • (2008) Clin. Rheumatol. , vol.27 , Issue.7 , pp. 927-932
    • Laas, K.1    Peltomaa, R.2    Kautiainen, H.3    Leirisalo-Repo, M.4
  • 36
    • 34447307138 scopus 로고    scopus 로고
    • Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis
    • Walsh CA, Minnock P, Slattery C et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology 46(7), 1148-1152 (2007
    • (2007) Rheumatology , vol.46 , Issue.7 , pp. 1148-1152
    • Walsh, C.A.1    Minnock, P.2    Slattery, C.3
  • 37
    • 34447316819 scopus 로고    scopus 로고
    • The conversion of infliximab to adalimumab in stable RA patients
    • Hutchinson D, Tier J, Soper S, Wilson G, Davis M. The conversion of infliximab to adalimumab in stable RA patients. Rheumatology 44(Suppl. 1), i72 (2005
    • (2005) Rheumatology , vol.44 , Issue.SUPPL. 1
    • Hutchinson, D.1    Tier, J.2    Soper, S.3    Wilson, G.4    Davis, M.5
  • 38
    • 67650137185 scopus 로고    scopus 로고
    • Dealing with immunogenicity of biologicals: Assessment and clinical relevance
    • Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: Assessment and clinical releVance. Curr. Opin. Rheumatol. 21(3), 211-215 (2009
    • (2009) Curr. Opin. Rheumatol. , vol.21 , Issue.3 , pp. 211-215
    • Wolbink, G.J.1    Aarden, L.A.2    Dijkmans, B.A.3
  • 39
    • 33845660797 scopus 로고    scopus 로고
    • Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab
    • Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54(12), 3782-3789 (2006
    • (2006) Arthritis Rheum. , vol.54 , Issue.12 , pp. 3782-3789
    • Bendtzen, K.1    Geborek, P.2    Svenson, M.3    Larsson, L.4    Kapetanovic, M.C.5    Saxne, T.6
  • 40
    • 30144436177 scopus 로고    scopus 로고
    • Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response
    • Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J. Rheumatol. 33(1), 31-36 (2006
    • (2006) J. Rheumatol. , vol.33 , Issue.1 , pp. 31-36
    • Haraoui, B.1    Cameron, L.2    Ouellet, M.3    White, B.4
  • 41
    • 33644931095 scopus 로고    scopus 로고
    • Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
    • Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis heum. 54(3), 711-715 (2006
    • (2006) Arthritis heum. , vol.54 , Issue.3 , pp. 711-715
    • Wolbink, G.J.1    Vis, M.2    Lems, W.3
  • 42
    • 70449725246 scopus 로고    scopus 로고
    • Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
    • Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68(11), 1739-1745 (2009)
    • (2009) Ann. Rheum. Dis. , vol.68 , Issue.11 , pp. 1739-1745
    • Radstake, T.R.1    Svenson, M.2    Eijsbouts, A.M.3
  • 43
    • 77951548027 scopus 로고    scopus 로고
    • Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: A cohort study
    • Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: A cohort study. Ann. Rheum. Dis. 69(5), 817-821 (2010
    • (2010) Ann. Rheum. Dis. , vol.69 , Issue.5 , pp. 817-821
    • Bartelds, G.M.1    Wijbrandts, C.A.2    Nurmohamed, M.T.3
  • 44
    • 79953906254 scopus 로고    scopus 로고
    • Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up
    • Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14), 1460-1468 (2011
    • (2011) JAMA , vol.305 , Issue.14 , pp. 1460-1468
    • Bartelds, G.M.1    Krieckaert, C.L.2    Nurmohamed, M.T.3
  • 45
    • 84872428460 scopus 로고    scopus 로고
    • Cimzia® (certolizumab pegol)prescribing information
    • Cimzia® (certolizumab pegol)prescribing information. UCB, Inc., GA, USA (2011
    • (2011) UCB Inc. GA USA
  • 46
    • 65249090248 scopus 로고    scopus 로고
    • Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
    • de Vries MK, Van der Horst-Bruinsma IE, Nurmohamed MT et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68(4), 531-535 (2009
    • (2009) Ann. Rheum. Dis. , vol.68 , Issue.4 , pp. 531-535
    • De Vries, M.K.1    Van Der Horst-Bruinsma, I.E.2    Nurmohamed, M.T.3
  • 47
    • 78751705197 scopus 로고    scopus 로고
    • The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
    • Jamnitski A, Bartelds GM, Nurmohamed MT et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann. Rheum. Dis. 70(2), 284-288 (2011
    • (2011) Ann. Rheum. Dis. , vol.70 , Issue.2 , pp. 284-288
    • Jamnitski, A.1    Bartelds, G.M.2    Nurmohamed, M.T.3
  • 48
    • 84872429799 scopus 로고    scopus 로고
    • Simponi® (golimumab)prescribing information
    • Simponi® (golimumab)prescribing information. Janssen Biotech, Inc., PA, USA (2011
    • (2011) Janssen Biotech Inc. PA USA
  • 49
    • 33846079219 scopus 로고    scopus 로고
    • The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and meta-analysis
    • Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and meta-analysis. J. Rheumatol. 33(12), 2398-2408 (2006
    • (2006) J. Rheumatol. , vol.33 , Issue.12 , pp. 2398-2408
    • Gartlehner, G.1    Hansen, R.A.2    Jonas, B.L.3    Thieda, P.4    Lohr, K.N.5
  • 50
    • 38749141455 scopus 로고    scopus 로고
    • Systematic review: Comparative effectiveness and harms of diseasemodifying medications for rheumatoid arthritis
    • Donahue KE, Gartlehner G, Jonas DE et al. Systematic review: Comparative effectiveness and harms of diseasemodifying medications for rheumatoid arthritis. Ann. Intern. Med. 148(2), 124-134 (2008
    • (2008) Ann. Intern. Med. , vol.148 , Issue.2 , pp. 124-134
    • Donahue, K.E.1    Gartlehner, G.2    Jonas, D.E.3
  • 51
    • 84855352586 scopus 로고    scopus 로고
    • A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: A Bayesian approach
    • Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: A Bayesian approach. Ann. Rheum. Dis. 71(2), 225-230 (2012
    • (2012) Ann. Rheum. Dis. , vol.71 , Issue.2 , pp. 225-230
    • Schmitz, S.1    Adams, R.2    Walsh, C.D.3    Barry, M.4    FitzGerald, O.5
  • 52
    • 33845482745 scopus 로고    scopus 로고
    • A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
    • Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in dults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 1-266 (2006
    • (2006) Health Technol. Assess. , vol.10 , Issue.42 , pp. 1-266
    • Chen, Y.F.1    Jobanputra, P.2    Barton, P.3
  • 53
    • 78751685797 scopus 로고    scopus 로고
    • Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
    • Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol. Drug Saf. 20(2), 119-130 (2011
    • (2011) Pharmacoepidemiol. Drug Saf. , vol.20 , Issue.2 , pp. 119-130
    • Askling, J.1    Fahrbach, K.2    Nordstrom, B.3    Ross, S.4    Schmid, C.H.5    Symmons, D.6
  • 54
    • 84872427050 scopus 로고    scopus 로고
    • Comparison of survival rates of TNFa antagonists in rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriatic arthritis in Czech national registry ATTRA
    • Pavelka K, Zavada J, Mann H, Chroust K, Bure?ova L, Vencovsk? J. Comparison of survival rates of TNFa antagonists in rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriatic arthritis in Czech national registry ATTRA. Ann. Rheum. Dis. 6(Suppl. 3), 525 (2010
    • (2010) Ann. Rheum. Dis. , vol.6 , Issue.SUPPL. 3 , pp. 525
    • Pavelka, K.1    Závada, J.2    Mann, H.3    Chroust, K.4    Burešová, L.5    Vencovský, J.6
  • 55
    • 66249124273 scopus 로고    scopus 로고
    • Swiss clinical quality management physicians comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
    • Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 61(5), 560-568 (2009
    • (2009) Arthritis Rheum. , vol.61 , Issue.5 , pp. 560-568
    • Du Pan, S.M.1    Dehler, S.2    Ciurea, A.3    Ziswiler, H.R.4    Gabay, C.5    Finckh, A.6
  • 56
    • 32444443730 scopus 로고    scopus 로고
    • The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden
    • Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum. 54(2), 600-606 (2006
    • (2006) Arthritis Rheum. , vol.54 , Issue.2 , pp. 600-606
    • Kristensen, L.E.1    Saxne, T.2    Geborek, P.3
  • 57
    • 12844254964 scopus 로고    scopus 로고
    • Granulomatous infections due to tumor necrosis factor blockade: Correction
    • Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin. Infect. Dis. 39(8), 1254-1255 (2004
    • (2004) Clin. Infect. Dis. , vol.39 , Issue.8 , pp. 1254-1255
    • Wallis, R.S.1    Broder, M.2    Wong, J.3    Beenhouwer, D.4
  • 58
    • 1042290327 scopus 로고    scopus 로고
    • Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
    • Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50(2), 372-379 (2004
    • (2004) Arthritis Rheum. , vol.50 , Issue.2 , pp. 372-379
    • Wolfe, F.1    Michaud, K.2    Anderson, J.3    Urbansky, K.4
  • 59
    • 34250656516 scopus 로고    scopus 로고
    • Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection
    • Biobadaser Group.
    • Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 57(5), 756-761 (2007
    • (2007) Arthritis Rheum. , vol.57 , Issue.5 , pp. 756-761
    • Gómez-Reino, J.J.1    Carmona, L.2    Angel Descalzo, M.3
  • 60
    • 67650096563 scopus 로고    scopus 로고
    • Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal ntibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry
    • Research Axed on Tolerance of Biotherapies Group
    • Tubach F, Salmon D, Ravaud P et al.; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal ntibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 60(7), 1884-1894 (2009
    • (2009) Arthritis Rheum. , vol.60 , Issue.7 , pp. 1884-1894
    • Tubach, F.1    Salmon, D.2    Ravaud, P.3
  • 61
    • 77949477575 scopus 로고    scopus 로고
    • Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the british society for rheumatology biologics register (bsrbr)ann
    • Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)Ann. Rheum. Dis. 69(3), 522-528 (2010)
    • (2010) Rheum. Dis. , vol.69 , Issue.3 , pp. 522-528
    • Dixon, W.G.1    Hyrich, K.L.2    Watson, K.D.3
  • 62
    • 84877020318 scopus 로고    scopus 로고
    • The influence of anti-TNF therapy upon the incidence and severity of serious lower respiratory tract infections in patients with rheumatoid arthritis: Results from the BSR biologics register (BSBR
    • Dixon W, Hyrich K, Watson K, Lunt M, Symmons D. The influence of anti-TNF therapy upon the incidence and severity of serious lower respiratory tract infections in patients with rheumatoid arthritis: Results from the BSR biologics register (BSBR)Rheumatology 47(Suppl. 2), ii47 (2008
    • (2008) Rheumatology , vol.47 , Issue.SUPPL. 2 , pp. 247
    • Dixon, W.1    Hyrich, K.2    Watson, K.3    Lunt, M.4    Symmons, D.5
  • 63
    • 60749125474 scopus 로고    scopus 로고
    • Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents
    • Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7), 737-744 (2009
    • (2009) JAMA , vol.301 , Issue.7 , pp. 737-744
    • Strangfeld, A.1    Listing, J.2    Herzer, P.3
  • 64
    • 79952360597 scopus 로고    scopus 로고
    • RATIO group drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
    • Salmon-Ceron D, Tubach F, Lortholary O et al.; RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 70(4), 616-623 (2011
    • (2011) Ann. Rheum. Dis. , vol.70 , Issue.4 , pp. 616-623
    • Salmon-Ceron, D.1    Tubach, F.2    Lortholary, O.3
  • 65
    • 77954232611 scopus 로고    scopus 로고
    • Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents
    • Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents. Rheumatology 49(7), 1215-1228 (2010
    • (2010) Rheumatology , vol.49 , Issue.7 , pp. 1215-1228
    • Horiuchi, T.1    Mitoma, H.2    Harashima, S.3    Tsukamoto, H.4    Shimoda, T.5
  • 66
    • 70350548170 scopus 로고    scopus 로고
    • Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment
    • Askling J, Van Vollenhoven RF, Granath F et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum. 60(11), 3180-3189 (2009
    • (2009) Arthritis Rheum. , vol.60 , Issue.11 , pp. 3180-3189
    • Askling, J.1    Van Vollenhoven, R.F.2    Granath, F.3
  • 67
    • 75849118366 scopus 로고    scopus 로고
    • Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry
    • Mariette X, Tubach F, Bagheri H et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis 69(2), 400-408 (2010
    • (2010) Ann. Rheum. Dis , vol.69 , Issue.2 , pp. 400-408
    • Mariette, X.1    Tubach, F.2    Bagheri, H.3
  • 68
    • 77952675245 scopus 로고    scopus 로고
    • Lymphoma, rheumatoid arthritis, and TNFalpha antagonists
    • Mariette X. Lymphoma, rheumatoid arthritis, and TNFalpha antagonists. Joint Bone Spine 77(3), 195-197 (2010
    • (2010) Joint Bone Spine , vol.77 , Issue.3 , pp. 195-197
    • Mariette, X.1
  • 69
    • 84864238239 scopus 로고    scopus 로고
    • Comparing medical utilization and expenditures between switchers and non switchers for tumor necrosis factor inhibitors (anti-TNFs)in the treatment of rheumatoid arthritis the american college of rheumatology 71st annual scientific meeting program book
    • Nair KV, Tang B, Van Den Bos J, Zhang V, Naim A, Rahman M. Comparing medical utilization and expenditures between switchers and non switchers for tumor necrosis factor inhibitors (anti-TNFs)in the treatment of rheumatoid arthritis The American College of Rheumatology 71st Annual Scientific Meeting Program Book. Abstract CRC46 (2007
    • (2007) Abstract CRC46
    • Nair, K.V.1    Tang, B.2    Van Den Bos, J.3    Zhang, V.4    Naim, A.5    Rahman, M.6
  • 70
    • 84864231687 scopus 로고    scopus 로고
    • Health care costs associated with switching of biologic disease modifying anti-rheumatic drugs
    • Meissner B, Trivedi D, Rosenblatt L, You M, Hebden T. Health care costs associated with switching of biologic disease modifying anti-rheumatic drugs. J. Manage. Care Pharm. 17(7), 560 (2011
    • (2011) J. Manage. Care Pharm. , vol.17 , Issue.7 , pp. 560
    • Meissner, B.1    Trivedi, D.2    Rosenblatt, L.3    You, M.4    Hebden, T.5
  • 71
    • 79955646543 scopus 로고    scopus 로고
    • Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: Evidence from clinical practice
    • Moots RJ, Haraoui B, Matucci-Cerinic M et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: Evidence from clinical practice. Clin. Exp. Rheumatol. 29(1), 26-34 (2011
    • (2011) Clin. Exp. Rheumatol. , vol.29 , Issue.1 , pp. 26-34
    • Moots, R.J.1    Haraoui, B.2    Matucci-Cerinic, M.3
  • 72
    • 8844282618 scopus 로고    scopus 로고
    • Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: A retrospective cohort study
    • Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: A retrospective cohort study. BMC Musculoskelet. Disord. 5(1), 36 (2004)
    • (2004) BMC Musculoskelet. Disord. , vol.5 , Issue.1 , pp. 36
    • Gilbert Jr., T.D.1    Smith, D.2    Ollendorf, D.A.3
  • 73
    • 65549157439 scopus 로고    scopus 로고
    • Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population
    • Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin. Ther. 31(4), 825-835 (2009
    • (2009) Clin. Ther. , vol.31 , Issue.4 , pp. 825-835
    • Ollendorf, D.A.1    Klingman, D.2    Hazard, E.3    Ray, S.4
  • 74
    • 78349295323 scopus 로고    scopus 로고
    • Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis
    • Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am. J. Health Syst. Pharm. 67(15), 1281-1287 (2010
    • (2010) Am. J. Health Syst. Pharm. , vol.67 , Issue.15 , pp. 1281-1287
    • Harrison, D.J.1    Huang, X.2    Globe, D.3
  • 75
    • 77956415622 scopus 로고    scopus 로고
    • Impact of dosing on treatment with TNF inhibitors: Managing dose adjustment
    • Combe B. Impact of dosing on treatment with TNF inhibitors: managing dose adjustment. Clin. Exp. Rheumatol. 28(3 Suppl. 59), S13-S17 (2010
    • (2010) Clin. Exp. Rheumatol. , vol.28 , Issue.3 SUPPL. 59
    • Combe, B.1
  • 76
    • 84864254609 scopus 로고    scopus 로고
    • Comparative cost-efficacy of biologic agents used to treat patients with rheumatoid arthritis
    • Trivedi D, Rosenblatt L, Hebden T. Comparative cost-efficacy of biologic agents used to treat patients with rheumatoid arthritis. J. Manage. Care Pharm. 17(7), 554 (2011
    • (2011) J. Manage. Care Pharm. , vol.17 , Issue.7 , pp. 554
    • Trivedi, D.1    Rosenblatt, L.2    Hebden, T.3
  • 77
    • 34547839821 scopus 로고    scopus 로고
    • Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: Results from the british society for rheumatology biologics registry
    • Brennan A, Bansback N, Nixon R et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology 46(8), 1345-1354 (2007
    • (2007) Rheumatology , vol.46 , Issue.8 , pp. 1345-1354
    • Brennan, A.1    Bansback, N.2    Nixon, R.3
  • 78
    • 58149526661 scopus 로고    scopus 로고
    • Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis
    • Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J. Rheumatol. 36(1), 16-26 (2009
    • (2009) J. Rheumatol. , vol.36 , Issue.1 , pp. 16-26
    • Davies, A.1    Cifaldi, M.A.2    Segurado, O.G.3    Weisman, M.H.4
  • 79
    • 80055081129 scopus 로고    scopus 로고
    • Assessing the cost-effectiveness of biologic agents for the management of moderate-tosevere rheumatoid arthritis in anti-TNF nadequate responders in Italy: A modelling approach
    • Cimmino MA, Leardini G, Salaffi F et al Assessing the cost-effectiveness of biologic agents for the management of moderate-tosevere rheumatoid arthritis in anti-TNF nadequate responders in Italy: A modelling approach. Clin. Exp. Rheumatol. 29(4), 633-641 (2011
    • (2011) Clin. Exp. Rheumatol. , vol.29 , Issue.4 , pp. 633-641
    • Cimmino, M.A.1    Leardini, G.2    Salaffi, F.3
  • 80
    • 61549117187 scopus 로고    scopus 로고
    • Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDs and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis
    • Russell A, Beresniak A, Bessette L et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDs and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin. Rheumatol. 28(4), 403-412 (2009
    • (2009) Clin. Rheumatol. , vol.28 , Issue.4 , pp. 403-412
    • Russell, A.1    Beresniak, A.2    Bessette, L.3
  • 81
    • 34447319146 scopus 로고    scopus 로고
    • Research in active rheumatoid arthritis (react)study group effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
    • Bombardieri S, Ruiz AA, Fardellone P et al.; Research in Active Rheumatoid Arthritis (ReAct)Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46(7), 1191-1199 (2007
    • (2007) Rheumatology , vol.46 , Issue.7 , pp. 1191-1199
    • Bombardieri, S.1    Ruiz, A.A.2    Fardellone, P.3
  • 82
    • 38549176118 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
    • Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 117(2), 244-279 (2008)
    • (2008) Pharmacol. Ther. , vol.117 , Issue.2 , pp. 244-279
    • Tracey, D.1    Klareskog, L.2    Sasso, E.H.3    Salfeld, J.G.4    Tak, P.P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.